Development of novel inhibitors for Aldo-Keto Reductase 1C3 (AKR1C3)

Show simple item record

dc.contributor.advisor Squire, C en
dc.contributor.advisor Flanagan, J en Hossain, Samira en 2014-10-22T20:26:44Z en 2014 en
dc.identifier.citation 2014 en
dc.identifier.uri en
dc.description Full text is available to authenticated members of The University of Auckland only. en
dc.description.abstract Breast and prostate cancers are the second leading cause of cancer-related death around the world. Although there are various risk factors associated with induction of these cancers, one of the causes is believed to be overexpression of hormones such as estrogen. Aldo-keto reductase 1C3 (AKR1C3) is a human enzyme that is involved in trans-activation of androgen and estrogen receptors. It catalyses NADPH-dependent reduction of carbonyl moieties on substrates such as 4-androstene-3,17-dione forming testosterone (a potent androgen), and on estrone forming 17β-estradiol (a potent estrogen). AKR1C3 also catalyses prostaglandin biosynthesis which leads to proliferative cellular signalling and tumour growth. Overexpression of AKR1C3 protein has been detected in tissues of breast and prostate cancer patients suggesting that AKR1C3 is a source of proliferative signals in hormone-dependent and hormone-independent breast and prostate cancer. Therefore this research was on the discovery and development of novel inhibitors of AKR1C3 with unique and diverse structures as potential anti-cancer therapeutics. Virtual screening was conducted to discover potential inhibitors from a 78,000 compound library. Twelve compounds were studied further by differential scanning fluorimetry as an initial screen for binding, followed by spectrophotometric and fluorometric inhibition assays. Another part of this project was to study how virtual screening of a fragment library correlates with the experimental fragment screening data of 492 fragments from the MayBridge Ro3 500 Library; differential scanning fluorimetry of all 492 compounds as experimental data was compared with computational screening data performed by the GOLD program and using the Goldscore fitness function. The Goldscore fitness function was shown to produce false positives and poor correlation was observed between the rankings of fragments on virtual screening and the experimental data, indicating the limitations of our virtual screening experiments to accurately predict potential ligands of AKR1C3. A final part of this project was to find a reliable and accurate docking method to allow us to predict the true binding modes of drug-like compound. Eighteen AKR1C3 ligands and four scoring functions were used in docking and compared to the previously determined crystal structures. Chemscore and ChemPLP scoring functions were shown to predict the true binding pose more accurately than other docking scoring functions. Keywords: AKR1C3, breast cancer, prostate cancer, anticancer drug, overexpression of AKR1C3, crystallisation, docking, virtual screening, inhibition en
dc.publisher ResearchSpace@Auckland en
dc.relation.ispartof Masters Thesis - University of Auckland en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights Restricted Item. Available to authenticated members of The University of Auckland. en
dc.rights.uri en
dc.title Development of novel inhibitors for Aldo-Keto Reductase 1C3 (AKR1C3) en
dc.type Thesis en The University of Auckland en Masters en
dc.rights.holder Copyright: The Author en
pubs.elements-id 459072 en
pubs.record-created-at-source-date 2014-10-23 en
dc.identifier.wikidata Q112905609

Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace